Results 1 to 10 of about 259,269 (302)

Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors [PDF]

Clinical and Experimental Dental Research, 2015
AbstractInterleukin‐6 (IL‐6) may play a pathological role in rheumatoid arthritis (RA) and periodontitis. Although the efficacy of medication with IL‐6 receptor inhibitor, tocilizumab (TCZ), has been demonstrated in the treatment of RA, very little is known about whether TCZ therapy affects periodontitis.
Tetsuo Kobayashi, , Ichiei Narita
exaly   +4 more sources

Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study [PDF]

Scientific Reports
During severe and critical COVID-19, therapeutic options remain scarce. Among interventions, the use of interleukin-6 receptor inhibitor (IL-6Ri) is especially controversial due to persistent uncertainty about their efficacy and safety.
Charlène Lefèvre, Théo Funck-Brentano, Marine Cachanado, Alexia Plocque, Maëlle Youinou, Audrey Fels, Frédéric Pène, Laurent Savale, David Montani, Olivier Voisin, Flore Bintein, Lucille Wildenberg, Axel Philippe, Stéphane Legriel, Nicolas Roche, Pierre-Régis Burgel, Marc Tran, Nicolas Noël, Christophe Baillard, Jacques Duranteau, Gilles Chatellier, Francois Philippart   +21 more
doaj   +6 more sources

Exploring the Role of Interleukin-6 Receptor Inhibitor Tocilizumab in Patients with Active Rheumatoid Arthritis and Periodontal Disease. [PDF]

J Clin Med, 2021
Background: The aim of our study was to explore the influence of weekly subcutaneous administration of interleukin-6 (IL-6) receptor inhibitor tocilizumab (TCZ) on periodontal status in a local longitudinal study of patients with rheumatoid arthritis (RA) and periodontal disease (PD).
Ancuța C, Chirieac R, Ancuța E, Țănculescu O, Solomon SM, Fătu AM, Doloca A, Iordache C.   +7 more
europepmc   +4 more sources

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +2 more sources

Human myeloma cells shed the interleukin‐6 receptor: inhibition by tissue inhibitor of metalloproteinase‐3 and a hydroxamate‐based metalloproteinase inhibitor [PDF]

British Journal of Haematology, 1998
Interleukin‐6 (IL‐6) is the major growth factor for human myeloma cells, exerting its effect through the IL‐6 receptor (IL‐6R). A soluble form of IL‐6R (sIL‐6R) has been identified, which increases the sensitivity of myeloma cells to IL‐6. In patients with multiple myeloma (MM), serum concentrations of sIL‐6R are elevated and associated with poor ...
Gillian Murphy, R G G Russell, Peter I Croucher   +2 more
exaly   +3 more sources

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods.
P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila   +17 more
doaj   +2 more sources

B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them.

Научно-практическая ревматология, 2019
The clinical efficacy and safety of interleukin-6 (IL-6) receptor blockade have been well studied, but the data on the impact of therapeutic inhibition of IL-6 on B cells are scarce and contradictory.
E. V. Gerasimova, T. V. Popkova, A. P. Aleksankin, A. V. Martynova, E. L. Nasonov   +4 more
doaj   +3 more sources

657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background Management of certain immune mediated adverse events (irAEs) can be challenging and may require prolonged/chronic immune suppression with corticosteroids or other immunosuppressant which could compromise and even reverse the efficacy of immune checkpoint inhibitors (ICI).
Adi Diab, Faisal Fa’ak, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Stephen Gruschkus, Daniel Johnson, Chantal Saberian, May Daher, Sang Kim, Maryam Buni, Kaysia Ludford   +12 more
doaj   +2 more sources

In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor [PDF]

Bioscience, Biotechnology, and Biochemistry, 2021
ABSTRACT Interleukin-6 (IL-6) binds to the IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study, we performed systematic evolution of ligands by exponential enrichment and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 n m,
Ando, Takehiro, Yamamoto, Mizuki, Takamori, Yukio, Tsukamoto, Keita, Fuji, Daisuke, Kawakami, Takashi   +5 more
openaire   +2 more sources

Spontaneous Regression of Metastatic Colorectal Cancer Following Discontinuation of an Interleukin-6 Receptor Inhibitor: A Case Report. [PDF]

Surg Case Rep
Miyake E, Taniguchi F, Nosaka M, Mouri K, Sato M, Kajioka H, Ogawa T, Watanabe M, Katsuda K, Iseki A, Sato Y, Tanakaya K, Aoki H.   +12 more
europepmc   +2 more sources